EGFR and urinary bladder carcinoma: For instance, MAPK phosphorylation was not inhibited in an EGFR-positive, gefitinib-resistant human bladder cancer cell line upon gefitinib treatment, while MAPK phosphorylation decreased in an EGFR-positive, gefitinib-sensitive cell line [164].